Diabetic foot ulcers (DFU) are one of the most frequent diabetes complications, with considerable morbidity and death. The current DFU standard of care (SOC) consists of four principles: (1) pressure reduction, (2) debridement, (3) infection control, and (4) revascularization when needed. Despite the present SOC, many DFU remain, necessitating a new strategy to manage these complicated wounds. The purpose of this study is to outline the present SOC as well as the most recent trends in adjunctive treatments that may become the future SOC in DFU therapy. Negative pressure wound therapy and hyperbaric oxygen therapy, bioengineered skin replacements, growth factors, shockwave therapy, and other treatments are examples. These new treatments have significantly improved DFU clinical outcomes in subgroups of DFU patients. However, much of the research is based on smaller trials with uneven patient selection and results, making it difficult to determine the real therapeutic value of these therapies.
While innovative treatments are promising for the multidisciplinary approach to DFU therapy, many lack sufficient data and their effectiveness is unknown.